Clinical Trials
Noxopharm Targets First-in-Human Clinical Trial for First-in-Class Drug SOF-SKN™
Highlights: First-in-human clinical trial for SOF-SKN™ and Sofra™ platform Efficient trial design with early results expected Le...
August 19, 2024 | News
Boston Immune Technologies and Therapeutics Secures Strategic Agreement with Otsuka's MSRD and $4M NIH/NCI Grant for Advancing Antibody Development
Boston Immune Technologies and Therapeutics, Inc. (BITT), a clinical stage developer of novel tumor necrosis factor superfamily receptor (TNFSR) antagonist...
August 19, 2024 | News
Vimgreen Pharmaceuticals Completes Enrollment for Phase 2 Trial of Novel A2A Receptor Antagonist in Parkinson's Disease
Vimgreen Pharmaceuticals, a science-driven pharmaceutical company focused on the modulation of adenosine signaling, announced the completion of enrollment ...
August 16, 2024 | News
Alfred Health Expands Oracle EHR to Enhance Cancer Care and Clinical Trial Access
Leading Victorian healthcare network, Alfred Health, has extended its long-standing Oracle Health footprint with Oracle's Oncology electroni...
August 14, 2024 | News
Mabwell's Nectin-4 Targeting ADC Receives Breakthrough Therapy Designation in China for Urothelial Carcinoma
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel Nectin-4 targeting ADC (R&D code: 9MW2821)...
August 13, 2024 | News
Lynk Pharmaceuticals Reports Positive Phase 1b Results for Skin-Restricted JAK Inhibitor LNK01004 in Atopic Dermatitis Treatment
Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, announced positiv...
August 13, 2024 | News
Biosyngen’s EBV-Specific CAR-T Therapy, BRG01, Secures FDA Approval for Pivotal Phase II Trial in U.S.
Biosyngen is proud to announce that the U.S. Food and Drug Administration (FDA) has approved its BRG01, an EBV-specific CAR-T cell therapy, to proceed with...
August 13, 2024 | News
Angiex Initiates Patient Dosing in Phase 1 Clinical Trial of AGX101, a First-in-Class TM4SF1-Directed Antibody-Drug Conjugate for Solid Cancers
Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that patient dosing has begun for t...
August 12, 2024 | News
Pulnovo Medical Launches Asia's First International Clinical Study on PADN at Singapore's National Heart Centre
Pulnovo Medical Limited,a globally recognized device pioneer in the treatment of Pulmonary Hypertension (PH) and Heart Failure (HF), is pleased to announce...
August 10, 2024 | News
NEC Bio Therapeutics and AGC Biologics Partner to Enhance Production of Personalized Cancer Vaccine
NEC Bio Therapeutics and AGC Biologics have announced a partnership to advance the production of NECVAX-NEO1, an orally delivered, bacteria-based D...
August 08, 2024 | News
Senhwa Biosciences Receives FDA Green Light for Phase I/II Trial of Silmitasertib in Pediatric Relapsed Refractory Solid Tumors
Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious disea...
August 07, 2024 | News
Oxford Nanopore Partners with Singapore's NPM to Map Genomic Diversity of Major Ethnic Groups
Oxford Nanopore Technologies (Oxford Nanopore) has announced a landmark project with Singapore's National Precision Medicine (NPM) programme, led by Precis...
August 05, 2024 | News
Bayer Submits New Drug Application to FDA for Elinzanetant, a Novel Non-Hormonal Treatment for Menopausal Hot Flashes
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency...
August 02, 2024 | News
Bridge Biotherapeutics Completes Patient Enrollment for Phase 2 Study of BBT-877 in IPF Treatment
Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis and cancer, an...
July 30, 2024 | News
Most Read
- Management of Relapsed/Refractory Multiple Myeloma
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
